Antigenicity and immunogenicity of RV144 vaccine AIDSVAX clade E envelope immunogen is enhanced by a gp120 N-terminal deletion

Journal of Virology

Volumn 87, Issue 3, 2013, Pages 1554-1568

  Alam, Munir S ^a   Liao, Hua Xin ^a   Tomaras, Georgia D ^a   Bonsignori, Mattia ^a   Tsao, Chun Yen ^a   Hwang, Kwan Ki ^a   Chen, Haiyan ^a   Lloyd Krissey E , E ^a   Bowman, Cindy ^a   Sutherland, Laura ^a   Jeffries, Thomas L ^a   Kozink, Daniel M ^a   Stewart, Shelley ^a   Anasti, Kara ^a   Jaeger, Frederick H ^a   Parks, Robert ^a   Yates, Nicole L ^a   Overman, Glenn R ^a   Sinangil, Faruk ^b   Berman, Phillip W ^c   Pitisuttithum, Punnee ^a   Kaewkungwal, Jaranit ^d   Nitayaphan, Sorachai ^e   Karasavva, Nicos ^e   Rerks Ngarm, Supachai ^f   Kim, Jerome H ^g   Michael, Nelson L ^g   Zolla Pazner, Susan ^h,i   Santra, Sampa ^j   Letvin, Norman L ^j   Harrison, Stephen C ^k,l   Haynes, Barton F ^a   more..

^a DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Global Solutions for Infectious Diseases   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d MAHIDOL UNIVERSITY   (Thailand)

^e ARMED FORCES RESEARCH INSTITUTE OF MEDICAL SCIENCES   (Thailand)

^f MINISTRY OF PUBLIC HEALTH   (Thailand)

^g WALTER REED ARMY INSTITUTE OF RESEARCH   (United States)

^h DEPARTMENT OF VETERANS AFFAIRS   (United States)

ⁱ NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^j BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^k HARVARD MEDICAL SCHOOL   (United States)

^l HOWARD HUGHES MEDICAL INSTITUTE   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

EPITOPE; GLYCOPROTEIN E; GLYCOPROTEIN GP 120; HUMAN IMMUNODEFICIENCY VIRUS RV 144 VACCINE; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; IMMUNOGLOBULIN G ANTIBODY; IMMUNOLOGICAL ADJUVANT; PALIVIZUMAB; UNCLASSIFIED DRUG; VIRUS ANTIGEN;

AMINO TERMINAL SEQUENCE; ANIMAL CELL; ANIMAL EXPERIMENT; ANTIBODY RESPONSE; ANTIBODY TITER; ANTIGEN BINDING; ANTIGENICITY; ARTICLE; CLADISTICS; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG POTENTIATION; HUMAN IMMUNODEFICIENCY VIRUS 1; IMMUNIZATION; IMMUNOGENICITY; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEPLETION; PROTEIN EXPRESSION; PROTEIN MODIFICATION; RHESUS MONKEY; VIRUS ENVELOPE;

EID: 84873051328     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.00718-12     Document Type: Article

References (45)

1. Rerks-Ngarm S, Pitisuttithum P, Nitayaphan S, Kaewkungwal J, Chiu J, Paris R, Premsri N, Namwat C, de Souza M, Adams E, Benenson M, Gurunathan S, Tartaglia J, McNeil JG, Francis DP, Stablein D, Birx DL, Chunsuttiwat S, Khamboonruang C, Thongcharoen P, Robb ML, Michael NL, Kunasol P, Kim JH, Investigators MOPH-TAVEG. 2009. Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N. Engl. J. Med. 361:2209-2220.
2. Berman PW. 1998. Development of bivalent rgp120 vaccines to prevent HIV type 1 infection. AIDS Res. Hum. Retroviruses 14:S277-S289.
3. Berman PW, Huang W, Riddle L, Gray AM, Wrin T, Vennari J, Johnson A, Klaussen M, Prashad H, Kohne deWit CC, Gregory TJ. 1999. Development of bivalent (B/E) vaccines able to neutralize CCR5- dependent viruses from the United States and Thailand. Virology 265:1-9.
4. Francis DP, Gregory T, McElrath MJ, Belshe RB, Gorse GJ, Migasena S, Kitayaporn D, Pitisuttitham P, Matthews T, Schwartz DH, Berman PW. 1998. Advancing AIDSVAX to phase 3: safety, immunogenicity, and plans for phase 3. AIDS Res. Hum. Retroviruses 14:325-331.
5. Lasky LA, Groopman JE, Fennie CW, Benz PM, Capon DJ, Dowbenko DJ, Nakamura GR, Nunes WM, Renz ME, Berman PW. 1986. Neutralization of the AIDS retrovirus by antibodies to a recombinant envelope glycoprotein. Science 233:209-212.
6. Flynn NM, Fortahl DN, Harro CD, Judson FN, Mayer KH, Para MF, rgp120 HIV Vaccine Study Group. 2005. Placebo-controlled phase 3 trial of a recombinant glycoprotein 120 vaccine to prevent HIV-1 infection. J. Infect. Dis. 191:654-665.
7. Pitisuttithum P. 2008. HIV vaccine research in Thailand: lessons learned. Expert Rev. Vaccines 7:311-317.
8. Liu J, Bartesaghi A, Borgnia MJ, Sapiro G, Subramaniam S. 2008. Molecular architecture of native HIV-1 gp120 trimers. Nature 455:109-113
9. Zhu P, Liu J, Bess J, Chertova E, Lifson JD, Grise H, Ofek GA, Taylor KA, Roux KH. 2006. Distribution and three-dimensional structure of AIDS virus envelope spikes. Nature 441:847-852.
10. Gorny MK, Stamatatos L, Volsky B, Revesz K, Williams C, Wang XH, Cohen S, Staudinger R, Zolla-Pazner S. 2005. Identification of a new quaternary neutralizing epitope on human immunodeficiency virus type 1 virus particles. J. Virol. 79:5232-5237.
11. Honnen WJ, Krachmarov C, Kayman SC, Gorny MK, Zolla-Pazner S, Pinter A. 2007. Type-specific epitopes targeted by monoclonal antibodies with exceptionally potent neutralizing activities for selected strains of human immunodeficiency virus type 1 map to a common region of the V2 domain of gp120 and differ only at single positions from the clade B consensus sequence. J. Virol. 81:1424-1432.
12. Kwong PD, Doyle ML, Casper DJ, Cicala C, Saleavitt Majeed S, Steenbeke TD, Venturi M, Chaiken I, Fung M, Katinge H, Parren PW, Robinson J, Van Ryk D, Wang L, Burton DR, Freire E, Wyatt R, Sodroski J, Hendrickson WA, Arthos J. 2002. HIV-1 evades antibodymediated neutralization through conformational masking of receptorbinding sites. Nature 420:678-682.
13. Harris A, Borgnia MJ, Shi D, Bartesaghi A, He H, Pejchal R, Kang YK, Depetris R, Marozsan AJ, Sanders RW, Klasse PJ, Milne JL, Wilson IA, Olson WC, Moore JP, Subramaniam S. 2011. Trimeric HIV-1 glycoprotein gp140 immunogens and native HIV-1 envelope glysoproteins display the same and open quaternary molecular architectures. Proc. Natl. Acad. Sci. U. S. A. 108:11440-11445.
14. Finzi A, Pacheco B, Zeng X, Do Kwon Y, Kwong PD, Sodroski J. 2010. Conformational characterization of aberrant disulfide-linked HIV-1 gp120 dimers secreted from overexpressing cells. J. Virol. Methods 168: 155-161.
15. Gorny MK, Moore JP, Conley AJ, Karwowska S, Sodroski J, Williams C, Burda S, Boots LJ, Zolla-Pazner S. 1994. Human anti-V2 monoclonal antibody that neutralizes primary but not laboratory isolates of human immunodeficiency virus type 1. J. Virol. 68:8312-8320.
16. Kayman SC, Wu Z, Revesz K, Chen H, Kopelman R, Pinter A. 1994. Presentation of native epitopes in the V1V2 and V3 regions of human immunodeficiency virus type I gp120 by fusion glycoproteins containing isolated gp120 domains. J. Virol. 68:400-410.
17. McLellan J, Pancera M, Carrico C, Gorman J, Julien JP, Khayat R, Louder R, Pejchal R, Sastry M, Dai K, O'Dell S, Patel N, Shahzad-ul Hussan S, Yang Y, Zhang B, Zhou T, Zhu J, Boyington JC, Chuang GY, Diwanji D, Georgiev I, Kwon YD, Lee D, Louder MK, Moquin S, Schmidt SD, Yang ZY, Bonsignori M, Crump JA, Kapiga SH, Sam NE, Haynes BF, Burton DR, Koff WC, Walker LM, Phogat S, Wyatt R, Orwenyo J, Wang LX, Arthos J, Bewley CA, Mascola JR, Nabel GJ, Schief WR, Ward AB, Wilson IA, Kwong PD. 2011. Structure of HIV-1 gp120 V1/V2 domain with broadly neutralizing antibody PG9. Nature 480:336-343.
18. Pinter A, Honnen WJ, He Y, Gorny MK, Zolla-Pazner S, Kayman SC. 2004. The V1/V2 domain of gp120 is a global regulator of the sensitivity of primary human immunodeficiency virus type 1 isolates to neutralization by antibodies commonly induced upon infection. J. Virol. 78:5205-5215.
19. Pinter A, Honnen WJ, Kayman SC, Trochev Wu OZ. 1998. Potent neutralization of primary HIV-1 isolates by antibodies directed against epitopes present in the V1/V2 domain of HIV-1 gp120. Vaccine 16:1803-1811.
20. Bonsignori M, Hwang KK, Chen X, Tsao CY, Morris L, Gray E, Marshall DJ, Crump JA, Kapiga SH, Sam NE, Sinangil F, Pancera M, Ypongpimg Y, Zhang B, Zhu J, Kwong PD, O'Dell S, Mascola JR, Wu Nabel L, Phogat GJS, Seaman MS, Seaman MS, Whitesides JF, Moody MA, Kelsoe G, Yang X, Sodroski J, Shaw GM, Montefiori DC, Kepler TB, Tomaras GD, Alam SM, Liao H-X, Haynes BF. 2011. Analysis of a clonal lineage of HIV-1 Envelope V2/V3 conformational epitope-specific broadly neutralizing antibodies and their inferred unmutated common ancestors. J. Virol. 85:9998-10009.
21. Walker LM, Phogat SK, Chan-Hui PY, Wagner D, Phung P, Goss JL, Wrin T, Simek MD, Fling S, Mitcham JL, Lehrman JK, Priddy FH, Olsen OA, Frey SM, Hammond PW, Kaminsky S, Zamb T, Moyle M, Koff WC, Poignard P, Burton DR. 2009. Broad and potent neutralizing antibodies from an African donor reveal a new HIV-1 vaccine target. Science 326:285-289.
22. Davenport T, Friend D, Ellingson K, Xu H, Caldwell Z, Sellhorn G, Kraft Z, Strong RK, Stamatatos L. 2011. Binding interactions between soluble HIV envelope glycoproteins and quaternary-structure-specific monoclonal antibodies PG9 and PG16. J. Virol. 85:7095-7107.
23. Haynes BF, McElrath GPMJ, Zolla-Pazner S, Tomaras GD, Alam SM, Evans DT, Montefiori DC, Karnasuta C, Sutthent R, Liao HX, DeVico AL, Lewis GK, Williams C, Pinter A, Fong Y, Janes H, DeCamp A, Huang Y, Rao M, Billings E, Karasavvas N, Robb ML, Ngauy V, de Souza MS, Paris R, Ferrari G, Bailer RT, Soderberg KA, Andrews C, Berman PW, Frahm N, De Rosa SC, Alpert MD, Yates NL, Shen X, Koup RA, Pitisuttithum P, Kaewkungwal J, Nitayaphan S, Rerks- Ngarm S, Michael NL, Kim JH. 2012. Immune-correlates analysis of an HIV-1 vaccine efficacy trial. N. Engl. J. Med. 366:1275-1286.
24. Liao H-X, Sutherland LL, Xia S-M, Brock ME, Scearce RM, Vanleeuwen S, Alam SM, McAdams M, Weaver EA, Camacho ZT, Ma B-J, Li Y, Decker JM, Nabel GJ, Montefiori DC, Hahn BH, Korber BT, Gao F, Haynes BF. 2006. A group M consensus envelope glycoprotein induces antibodies that neutralize subsets of subtype B and C HIV-1 primary viruses. Virology 353:268-282.
25. Keele BF, Giorgi EE, Salazar-Gonzalez JF, Decker JM, Pham KT, Salazar MG, Sun C, Grayson T, Wang S, Li H, Wei X, Jiang C, Kirchherr JL, Gao F, Anderson JA, Ping LH, Swanstrom R, Tomaras GD, Blattner WA, Goepfert PA, Kilby JM, Saag MS, Delwart EL, Busch MP, Cohen MS, Montefiori DC, Haynes BF, Gaschen B, Athreya GS, Lee HY, Wood N, Seoighe C, Perelson AS, Bhattacharya T, Korber BT, Hahn BH, Shaw GM. 2008. Identification and characterization of transmitted and early founder virus envelopes in primary HIV-1 infection. Proc. Natl. Acad. Sci. U. S. A. 105(21):7552-7557.
26. Tsao C, Liao H, Ma B, Chen H, Foulger AS, Lu X, Jaeger F, Hahn B, Shaw G, Swanstrom R, Cohen M, Kamanga G, Mascola J, Montefiori D, Alam MS, Haynes BF. 2010. Antigenicity and immunogenicity of transmitted/ founder HIV envelope oligomers compared to chronic HIV envelopes. AIDS Res. Hum. Retroviruses 10(01):A27.
27. Gorny MK, Williams C, Wang X, Volsky B, O'Neal T, Li L, Seaman MS, Zolla-Pazner S. 2012. Functional and immunochemical cross-reactivity of V2-specific monoclonal antibodies from human immunodeficiency virus type 1-infected individuals. Virology 427:198-207.
28. Alam SM, McAdams M, Boren D, Rak M, Scearce RM, Gao F, Camacho ZT, Gewirth D, Kelsoe G, Chen P, Haynes BF. 2007. The role of antibody polyspecificity and lipid reactivity in binding of broadly neutralizing anti- HIV-1 envelope human monoclonal antibodies 2F5 and 4E10 to glycoprotein 41 membrane proximal envelope epitopes. J. Immunol. 178: 4424-4435.
29. Alam SM, Morelli M, Dennison SM, Liao HX, Zhang R, Xia SM, Rits-Volloch S, Sun L, Harrison SC, Haynes BF, Chen B. 2009. Role of HIV membrane in neutralization by two broadly neutralizing antibodies. Proc. Natl. Acad. Sci. U. S. A. 106:20234-20239.
30. Alam SM, Scearce RM, Parks RJ, Plonk K, Plonk SG, Sutherland LL, Gorny MK, Zolla-Pazner S, Vanleeuwen S, Moody MA, Xia SM, Montefiori DC, Tomaras GD, Weinhold KJ, Karim SA, Hicks CB, Liao HX, Robinson J, Shaw GM, Haynes BF. 2008. Human immunodeficiency virus type 1 gp41 antibodies that mask membrane proximal region epitopes: antibody binding kinetics, induction, and potential for regulation in acute infection. J. Virol. 82:115-125.
31. Liu P, Overman RG, Yates NL, Alam SM, Vandergrift N, Chen Y, Graw F, Freel SA, Kappes JC, Ochsenbauer C, Montefiori DC, Gao F, Perelson AS, Cohen MS, Haynes BF, Tomaras GD. 2011. Dynamic antibody specificities and virion concentrations in circulating immune complexes in acute to chronic HIV-1 infection. J. Virol. 85:11196-11207.
32. Tomaras GD, Yates NL, Liu P, Qin L, Fouda GG, Chavez LL, Decamp AC, Parks RJ, Ashley VC, Lucas JT, Cohen M, Eron J, Hicks CB, Liao HX, Self SG, Landucci G, Forthal DN, Weinhold KJ, Keele BF, Hahn BH, Greenberg ML, Morris L, Karim SS, Blattner WA, Montefiori DC, Shaw GM, Perelson AS, Haynes BF. 2008. Initial B-cell responses to transmitted human immunodeficiency virus type 1: virion-binding immunoglobulinM( IgM) and IgG antibodies followed by plasma anti-gp41 antibodies with ineffective control of initial viremia. J. Virol. 82:12449-12463.
33. Safsten P, Klakamp SL, Drake AW, Karlsson R, Myszka DG. 2006. Screening antibody-antigen interactions in parallel using BIAcore A100. Anal. Biochem. 353:181-190.
34. Kasturi SP, Skountozi I, Albrecht RA, Koutsonanos D, Hua T, Nakaya HI, Ravindran R, Stewart S, Alam M, Kwissa M, Villinger F, Murthy N, Steel J, Jacob J, Hogan RJ, García-Sastre A, Compans R, Pulendran B. 2011. Programming the magnitude and persistence of antibody responses with innate immunity. Nature 470:543-547.
35. Flynn BJ, Kastenmuller K, Willie-Reece U, Tomaras GD, Alam SM, Lindsay RW, Salazar AM, Perdiguero B, Gomez CE, Wagner R, Esteban M, Park CG, Trumpfheller C, Keler T, Panteleo G, Steinman RM, Seder R. 2011. Immunization with HIV Gag targeted to dendritic cells followed by recombinant New York Vaccinia virus induces robust T-cell immunity in nonhuman primates. Proc. Natl. Acad. Sci. U. S. A. 108:7131-7136.
36. Bonsignori M, Moody JPMA, Alpert MD, Chen X, Hwang K-K, Gilbert PB, Huang YT, Gurley C, Kozink D, MArshall DJ, Whitesides JF, Tsao C-Y, Kaewkungwal J, Nitayaphan S, Pitisuttithum P, Rerks-Ngam S, Kim JH, Michael NL, Tomaras GD, Lewis GK, Devico A, Evans DT, Ferrari G, Liao HX, Haynes BF. 2012. ADCC-mediating antibodies from an HIV-1 vaccine efficacy trial target multiple epitopes and preferentially use the VH1 gene family. J. Virol. 86:11521-11532.
37. Liao HX, Levesque MC, Nagel A, Dixon A, Zhang R, Walter E, Parks R, Whitesides J, Marshall DJ, Hwang KK, Yang Y, Chen X, Gao F, Munshaw S, Kepler TB, Denny T, Moody MA, Haynes BF. 2009. High-throughput isolation of immunoglobulin genes from single human B cells and expression as monoclonal antibodies. J. Virol. Methods 158:171-179.
38. Wrammert J, Smith K, Miller J, Langley WA, Kokko K, Larsen C, Zheng NY, Mays I, Garman L, Helms C, James J, Air GM, Capra JD, Ahmed R, Wilson PC. 2008. Rapid cloning of high-affinity human monoclonal antibodies against influenza virus. Nature 453:667-671.
39. Dennison SM, Sutherland LL, Jaeger FH, Anasti KM, Parks R, Stewart S, Bowman C, Xia SM, Zhang R, Shen X, Scearce RM, Ofek G, Yang Y, Kwong PD, Santra S, Liao HX, Tomaras G, Letvin NL, Chen B, Alam SM, Haynes BF. 2011. Induction of antibodies in rhesus macaques that recognize a fusion-intermediate conformation of HIV-1 gp41. PLoS One 6:e27824. doi:10.1371/journal.pone.0027824.
40. Ma BJ, Alam SM, Go EP, Lu X, Desaire H, Tomaras GD, Bowman C, Sutherland LL, Scearce RM, Santra S, Letvin NL, Kepler TB, Liao HX, Haynes BF. 2011. Envelope deglycosylation enhances antigenicity of HIV-1 gp41 epitopes for both broad neutralizing antibodies and their unmutated ancestor antibodies. PLoS Pathog. 7:e1002200. doi:10.1371 /journal.ppat.1002200.
41. Ferrari G, Pollara J, Kozink D, Harms T, Drinker M, Freel S, Moody MA, Alam SM, Tomaras GD, Ochsenbauer C, Kappes JC, Shaw GM, Hoxie JA, Robinson JE, Haynes BF. 2011. An HIV-1 gp120 envelope human monoclonal antibody that recognizes a C1 conformational epitope mediates potent antibody-dependent cellular cytotoxicity (ADCC) activity and defines a commonADCCepitope in human HIV-1 serum. J. Virol. 85:7029-7036.
42. VanCott TC, Bethke FR, Polonis VR, Gorny MK, Zolla-Pazner S, Redfield RR, Birx DL. 1994. Dissociation rate of antibody-gp120 binding interactions is predictive of V3-mediated neutralization of HIV-1. J. Immunol. 153:449.
43. Bonsignori M, Wu X, Moody MA, Liao H, Hwang K, Crump JA, Capiga SH, Sam NE, Tomaras GD, Chen X, Tsao C, Alam SM, Nabel GJ, Kwong PD, Morris L, Montefiori D, Mascola JR, Haynes BF. 2011. Isolation of CD4-binding site and V2/V3 conformational (quaternary) broadly neutralizing antibodies from the same HIV-1 infected African subject. AIDS Res. Hum. Retroviruses 27:A120.
44. Billings EA, Karasavvas N, de Souza MS, Currier J, Pitisuttithum P, Kaewkunwal J, Nitayaphan S, Gilbert PB, Tomaras GD, Zolla-Pazner SB, Haynes BF, Michael NL, Rerks-Ngarm S, Kim JH, Rao M. 2011. Surface plasmon resonance analysis of anti-gp120 V2-specific IgG antibodies generated in the RV144 Thai Trial. AIDS Res. Hum. Retroviruses 27:21.
45. Zolla-Pazner S, Cardozo T, Decamp A, Haynes B, Kim J, Kong X, Michael N, Rerks-Ngam S, Williams C. 2011. V2-reactive antibodies in RV144 vaccinees' plasma. AIDS Res. Hum. Retroviruses 27:A21.